Results from a phase 2 clinical trial designed and overseen by researchers at Mass General Brigham Cancer Institute show that the investigational medication mezagitamab can effectively boost platelet counts in patients with immune thrombocytopenia (ITP), an autoimmune disease characterized by elevated platelet destruction and reduced platelet production that increases bleeding risk and compromises quality of life.

The University of Cincinnati has enrolled the first patients in Peptilogics’ RETAIN trial, testing the effectiveness of an investigational drug in patients with prosthetic joint infections following total knee replacement.

A new Yale study reveals the distinct timing effects of maternal and paternal depression on adult mental health outcomes in the next generation, including influences on depression, anxiety, and psychotic disorders. 

A research team led by Kieran O’Donnell at Yale School of Medicine (YSM) found pregnancy to be a sensitive period, with exposure to high levels of maternal depression during this time alone predictive of psychosis risk in adult offspring. This points to the importance of adequate mental health support during pregnancy, they say.